Je was op zoek naar: topoisomerase (Engels - Maltees)

inhibition of topoisomerase ii.
inibizzjoni ta’ topoisomerase ii.

antineoplastic effect: inhibition of topoisomerase ii.
effett antineoplastiku: inibizzjoni ta ’ topoisomerase ii.

these effects can be attributed to inhibition of topoisomerase ii.
dawn l-effetti jistgħu jiġu attribwiti għall-inibizzjoni ta’ topoisomerase ii.

the primary targets for pradofloxacin are the bacterial dna gyrase and topoisomerase iv enzymes.
il-miri ewlenin għal pradofloxacin huma l-enzimi batterjali tad-dna gyrase u topoisomerase iv.

it blocks an enzyme called topoisomerase i, which is involved in the division of dna.
din timblokka enzim, it- topoisomerażi i, li għandu x' jaqsam mal - moltiplikazzjoni tad- dna.

irinotecan belongs to a group of cancer medicines called ‘topoisomerase inhibitors’.
irinotecan jappartjeni għal grupp ta’ mediċini kontra l-kanċer imsejħa 'inibituri ta’ topoisomerase'.

resistance to levofloxacin is most often acquired through a stepwise process by target site mutations in dna gyrase and topoisomerase iv.
ir-reżistenza għal levofloxacin fil-biċċa l-kbira tinkiseb permezz ta’ proċess pass pass minn mutazzjonijiet fis-sit fil-mira f’dna gyrase u topoisomerase iv.

it blocks an enzyme called topoisomerase i, which is involved in copying cell dna, which is needed to make new cells.
din timblokka l-enzima msejħa topoisomerase i, li hija involuta fl-ikkupjar tad-dna taċ-ċelloli, li huwa meħtieġ biex isiru ċelloli ġodda.

reversible association between pradofloxacin and dna gyrase or dna topoisomerase iv in the target bacteria results in inhibition of these enzymes and rapid death of the bacterial cell.
l-assoċjazzjoni riversibbli bejn pradofloxacin u dna gyrase jew dna topoisomerase iv fil-batterji fil-mira tirrżulta f’inibizzjoni ta’ dawn l-enzimi u l-mewta rapida taċ-ċelluli batterjali.

the active substance in hycamtin, topotecan, is an anticancer medicine that belongs to the group ‘ topoisomerase inhibitors’.
is- sustanza attiva f' hycamtin, topotecan, hija mediċina ta 'kontra l- kanċer li tagħmel parti mill- grupp ta' 'inibituri ta' topoisomerażi '.

topotecan inhibits topoisomerase-i by stabilising the covalent complex of enzyme and strand-cleaved dna which is an intermediate of the catalytic mechanism.
topotecan jinibixxi topoisomerase-i billi jistabiliżża lill-kumpless kovalenti tal- enżima u lid- dna maqsum bl-istrand li huwa l-proċess intermedjarju tal-mekaniżmu katalitiku.

doxorubicin may exert its antitumour and toxic effects by a number of mechanisms including inhibition of topoisomerase ii, intercalation with dna and rna polymerases, free radical formation and membrane binding.
doxorubicin għandu mnejn jeżerċita l-effetti ta’ kontra t-tumur u l-effetti tossiċi b’numru ta’ mekkaniżmi li jinkludu l-impediment ta’ topoisomerase ii, interkalazzjoni b’ dna u rna polymerases, formazzjoni ta’ radikali ħielsa u tirbit mar-riti.

the bactericidal action of moxifloxacin results from the inhibition of both type ii topoisomerases (dna gyrase and topoisomerase iv) required for bacterial dna replication, transcription and repair.
l- azzjoni batteriċida ta ’ moxifloxacin tirriżulta mill- inibizzjoni taż- żewġ topoisomerases tat- tip ii (dna gyrase u topoisomerase iv) meħtieġa għar- replikazzjoni, transkrizzjoni u tiswija tad- dna tal - betterji.

by blocking two enzymes called ‘dna gyrase’ and ‘topoisomerase iv’, pradofloxacin stops the bacteria from growing and multiplying.
billi jimblokka żewġ enzimi msejħin ‘dna gyrase’ u ‘topoisomerase iv’, pradofloxacin iwaqqaf lill-batterji milli jikbru u jimmultiplikaw.

the anti-tumour activity of topotecan involves the inhibition of topoisomerase-i, an enzyme intimately involved in dna replication as it relieves the torsional strain introduced ahead of the moving replication fork.
l-attività ta’ topotecan kontra tumuri tikkonsisti fl-inibizzjoni ta’ topoisomerase-i, li hija enżima partikolarment involuta fir-replikazzjoni ta’ dna waqt li jneħħi l-istrejn tat-tidwir ta’ qabel il-moving replication fork.

the way it works is not entirely clear, but may be linked to the way the medicine attaches to iron in the body to form a ‘chelate’ and to its effect on some enzymes, such as topoisomerase ii.
il-mod kif taħdem mhuwiex ċar għal kollox, iżda jista’ jkun marbut mal-mod kif il-mediċina teħel mal-ħadid fil-ġisem biex tifforma ‘chelate’ u mal-effett tiegħu fuq xi enżimi, bħal topoisomerase ii.

as a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type ii topoisomerase (dna-gyrase) and topoisomerase iv, required for bacterial dna replication, transcription, repair and recombination.
bħala sustanza fluoroquinolone kontra l- batterja, l- azzjoni batteriċida ta ’ ciprofloxacin tirriżulta mill - inibizzjoni taż- żewġ topoisomerase tat- tipi ii (dna- gyrase) u ta ’ topoisomerase iv, li huma meħtieġa għar- replikazzjoni, transkrizzjoni, tiswija u rikombinazzjoni tad- dna tal- batterja.